FDA approves AstraZeneca’s novel hypertension pill Baxfendy

The U.S. Food and Drug Administration has cleared AstraZeneca’s new hypertension medication, Baxfendy, marking the first approval of a drug that works by inhibiting a blood‑pressure‑raising enzyme.

Baxfendy is a once‑daily tablet intended to be used alongside other antihypertensive agents for adults whose blood pressure remains uncontrolled despite multiple therapies. It targets the enzyme that synthesizes aldosterone, a mechanism that differs from existing treatments.

The approval rests on a late‑stage trial whose results appeared in the New England Journal of Medicine last summer. The study showed that two dosage levels of Baxfendy each produced a statistically significant reduction in seated blood pressure compared with placebo in patients with resistant hypertension.

The drug was generally well tolerated. Most adverse events were mild, with the most frequent being muscle spasms, dizziness, low blood pressure, and abnormal sodium or potassium levels.

AstraZeneca executives describe Baxfendy as a potential blockbuster, projecting annual sales of $5 billion or more if the product meets market expectations.